| target_debate_target | Should GPR109A (Hydroxycarboxylic Acid Receptor 2 (HCAR2)) be prioritized as a t | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should MAP6 (Microtubule-associated protein 6) be prioritized as a therapeutic t | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should GFAP (Glial fibrillary acidic protein) be prioritized as a therapeutic ta | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should ST3GAL2 (ST3 beta-galactoside alpha-2,3-sialyltransferase 2) be prioritiz | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should MTOR (Mechanistic Target of Rapamycin) be prioritized as a therapeutic ta | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should CSGA (CSGA Protein) be prioritized as a therapeutic target for neurodegen | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should CNO (Cappuccino) be prioritized as a therapeutic target for neurodegenera | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should CHMP4B (Charged multivesicular body protein 4B) be prioritized as a thera | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should SLC16A2 (Monocarboxylate transporter 8) be prioritized as a therapeutic t | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should CLDN1 (Claudin-1) be prioritized as a therapeutic target for neurodegener | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should CLDN5 (Claudin-5) be prioritized as a therapeutic target for neurodegener | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should ST8SIA1 (ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1) be | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should BRD4 (Bromodomain-containing protein 4) be prioritized as a therapeutic t | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should LOXL1-4 (Lysyl oxidase-like 1-4) be prioritized as a therapeutic target f | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should CAV1 (Caveolin-1) be prioritized as a therapeutic target for neurodegener | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should FLOT1 (Flotillin 1) be prioritized as a therapeutic target for neurodegen | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should AQP4 (Aquaporin-4) be prioritized as a therapeutic target for neurodegene | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should SGMS1 (Sphingomyelin synthase 1) be prioritized as a therapeutic target f | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should SIRT1 (NAD-dependent protein deacetylase sirtuin-1) be prioritized as a t | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should GAP43 (Growth associated protein 43) be prioritized as a therapeutic targ | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should FUT8 (Alpha-(1,6)-fucosyltransferase) be prioritized as a therapeutic tar | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should MCU (Mitochondrial calcium uniporter) be prioritized as a therapeutic tar | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should SGMS2 (Sphingomyelin synthase 2) be prioritized as a therapeutic target f | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should RELN (Reelin) be prioritized as a therapeutic target for neurodegeneratio | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should SNAP25 (Synaptosome associated protein 25) be prioritized as a therapeuti | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should PLA2G6 (Phospholipase A2 group VI) be prioritized as a therapeutic target | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should SETX (Senataxin) be prioritized as a therapeutic target for neurodegenera | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should FOXP3 (Forkhead box protein P3) be prioritized as a therapeutic target fo | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should CHR2 (Channelrhodopsin-2) be prioritized as a therapeutic target for neur | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should SYNCRIP (Heterogeneous nuclear ribonucleoprotein Q) be prioritized as a t | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should DGAT1 (Diacylglycerol O-Acyltransferase 1) be prioritized as a therapeuti | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should HSPG2 (Heparan Sulfate Proteoglycan 2) be prioritized as a therapeutic ta | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should PLIN2 (Perilipin 2) be prioritized as a therapeutic target for neurodegen | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should ST6GAL1 (ST6 beta-galactoside alpha-2,6-sialyltransferase 1) be prioritiz | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should PYCARD (Apoptosis-associated speck-like protein containing CARD) be prior | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should CERS2 (Ceramide synthase 2) be prioritized as a therapeutic target for ne | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should NLGN1 (Neuroligin-1) be prioritized as a therapeutic target for neurodege | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should CHMP2B (Charged multivesicular body protein 2B) be prioritized as a thera | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should SREBF2 (Sterol regulatory element binding transcription factor 2) be prio | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should SMPD1 (Sphingomyelin phosphodiesterase 1) be prioritized as a therapeutic | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should NPM1 (Nucleophosmin) be prioritized as a therapeutic target for neurodege | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should TARDBP (TAR DNA-binding protein 43) be prioritized as a therapeutic targe | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should CYP46A1 (Cytochrome P450 Family 46 Subfamily A Member 1) be prioritized a | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should OCLN (Occludin) be prioritized as a therapeutic target for neurodegenerat | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should ZO1 (Zonula occludens-1) be prioritized as a therapeutic target for neuro | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should COX4I1 (Cytochrome C Oxidase Subunit 4I1) be prioritized as a therapeutic | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should KDM6A (Lysine demethylase 6A) be prioritized as a therapeutic target for | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should PLA2G4A (Phospholipase A2 group IVA) be prioritized as a therapeutic targ | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should MLCK (Myosin light chain kinase) be prioritized as a therapeutic target f | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should ABCB1 (P-glycoprotein) be prioritized as a therapeutic target for neurode | 0.50 | 0 | 4 | completed | 2026-04-22 | |